There are currently 1958 clinical trials in Philadelphia, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Pennsylvania, Children's Hospital of Philadelphia, Fox Chase Cancer Center and Thomas Jefferson University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Wearable Wireless Respiratory Monitoring System That Detects and Predicts Opioid Induced Respiratory Depression
NCT06442488
Recruiting
An observational study will be conducted in approximately 14 participants to evaluate the ability of a wearable, wireless acoustic Respiratory Monitoring System (RMS) to accurately measure a participant's respiratory rate, tidal volume, minute ventilation, and duration of apnea in a noisy environment. Sensor accuracy will be measured with adaptive filtering and active noise cancellation turned on versus turned off.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
05/29/2024
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Respiratory Insufficiency, Clinical Deterioration
Register for Updates
DISE: Phenotyping Obstruction Patterns
NCT05050383
Recruiting
Drug-induced sleep endoscopy (DISE) represents an opportunity to evaluate the upper airway in sleep-like conditions. In its current clinical form, however, DISE does not routinely determine the functional impact of anatomic and neuromuscular factors on airflow obstruction. The investigators will apply nasal pressure (CPAP) during DISE to generate pressure-flow and pressure-area relationships, deriving functional determinants of upper airway obstruction during sleep. In addition, they will use o... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/29/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Obstructive Sleep Apnea
Register for Updates
ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
NCT05081245
Recruiting
ML-004-002 is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study that will enroll approximately 150 adolescent and adult subjects with ASD. The primary objective is to evaluate the efficacy of ML-004 compared with placebo in the improvement of social communication deficits in subjects with ASD.
Gender:
All
Ages:
Between 12 years and 45 years
Trial Updated:
05/28/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Autism Spectrum Disorder
Register for Updates
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
NCT05086315
Recruiting
This is an open-label, multicenter, Phase 1/Phase 2, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-leukemic activity of SAR443579 in various hematological malignancies.
Gender:
All
Ages:
1 year and above
Trial Updated:
05/28/2024
Locations: Children's Hospital of Philadelphia-3401 Civic Center Blvd Site Number : 8400013, Philadelphia, Pennsylvania
Conditions: Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia
Register for Updates
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
NCT06040099
Recruiting
The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with unresectable hepatocellular carcinoma (HCC) amenable to embolization.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
05/28/2024
Locations: Research Site, Philadelphia, Pennsylvania
Conditions: Hepatocellular Carcinoma (HCC)
Register for Updates
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT05769153
Recruiting
The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).
Gender:
All
Ages:
50 years and above
Trial Updated:
05/28/2024
Locations: MidAtlantic Retina Research, Philadelphia, Pennsylvania
Conditions: Neovascular Age-related Macular Degeneration (nAMD)
Register for Updates
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
NCT03275103
Recruiting
This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/28/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Multiple Myeloma
Register for Updates
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1
NCT02881320
Recruiting
The goals of this clinical study are to learn how Bictegravir/Emtricitabine/Tenofovir Alafenamide fixed dose combination (FDC) interacts with the body, confirm the dose, and also to learn more about the safety and tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide FDC in adolescents and children with HIV-1.
Gender:
All
Ages:
Between 1 month and 17 years
Trial Updated:
05/28/2024
Locations: St. Christopher's Hospital for Children/Section of Immunology, Philadelphia, Pennsylvania
Conditions: HIV-1 Infection
Register for Updates
A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).
NCT05039515
Recruiting
Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by the presence of bone in soft tissue where bone normally does not exist, known as Heterotopic Ossification (HO). It is often associated with painful, recurrent episodes of soft tissue swelling (flare-ups) that lead to abnormal stiffening and immobility (ankyloses) of major joints with cumulative and irreversible loss of movement and disability. This study will evaluate the efficacy of 2 dosing regi... Read More
Gender:
All
Ages:
5 years and above
Trial Updated:
05/28/2024
Locations: The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania +1 locations
Conditions: Fibrodysplasia Ossificans Progressiva
Register for Updates
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
NCT05378347
Recruiting
The purpose of this trial is to generate clinical evidence related to key performance outcomes of Endurant II/IIs Stent Graft Systems verses Gore Excluder / Excluder Conformable AAA Endoprosthesis in subjects with Abdominal Aortic Aneurysms. Subjects are randomized and imaging collected at all follow-up time points to assess the primary endpoint.
Gender:
All
Ages:
20 years and above
Trial Updated:
05/28/2024
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder), Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)
Register for Updates
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
NCT05047172
Recruiting
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.
Gender:
All
Ages:
30 years and above
Trial Updated:
05/28/2024
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania +2 locations
Conditions: Intracranial Arteriosclerosis, Stroke
Register for Updates
Genomic Risk in Retroperitoneal Sarcoma
NCT06436846
Recruiting
The protocol intends to explore the biology which may underlie recurrences of retroperitoneal liposarcoma. Surgery remains the only curative intent intervention for this disease. Often, tumors recur in locations within the retroperitoneum remote from the original primary tumor. This study hypothesizes that normal appearing retroperitoneal fat actually harbors underlying genetic changes which predispose to development of future liposarcoma. To accomplish this goal, retroperitoneal fat is sampled... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/28/2024
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Retroperitoneal Liposarcoma, Soft Tissue Sarcoma
Register for Updates